Nektar Therapeutics
NASDAQ:NKTR 4:00:00 PM EDT
| Market Cap (Intraday) | 291.19M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $22.81 |
| 50-Day MA | $13.28 |
| 200-Day MA | $14.51 |
Nektar Therapeutics Stock, NASDAQ:NKTR
455 Mission Bay Boulevard South, San Francisco, California 94158
United States of America
Phone: +1.415.482.5300
Number of Employees: 61
Description
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.